New research suggests cancer patients are at higher risk of dying from cardiovascular disease than the general population. According to the study, the results of which are published in the European Heart Journal, more than one in 10 cancer survivors die from heart and blood vessel problems, rather than their initial illness. Among the 3,234,256 cancer patients studied for the research, 38% died from cancer, while 11% died from cardiovascular diseases. Among the deaths from cardiovascular diseases, 76% were due to heart disease. The risk of dying from cardiovascular disease was also highest in the first year after a patient’s cancer diagnosis and among patients younger than 35. Among those cancer patients diagnosed before the age of 55 and who went on to survive their illness, the risk of dying from cardiovascular disease was more than 10 times higher than that for the general population. Meanwhile, patients with breast, prostate or bladder cancer were most likely to die from heart disease – but this is simply because these are the most common types of cancer. It is still unclear as to why cancer patients have a seemingly higher risk of heart disease, but their treatment itself or lifestyle factors, such as being overweight, drinking too much and not exercising, could be to blame, experts say.
A small study in the UK has found an unlikely ally in a strain of the common cold virus in the fight against bladder cancer. For the study, the findings of which appear in the journal Clinical Cancer Research, 15 patients with non-muscle invasive bladder cancer were intravenously given coxsackievirus (CVA21) ahead of scheduled surgery to remove their tumours. Post-surgery, when tissue samples were examined, there were signs the virus had targeted and killed cancer cells in the bladder. Furthermore, after the cancer cells had been killed, the virus reproduced and targeted other cancer cells. All other healthy cells were left intact. “The virus gets inside cancer cells and kills them by triggering an immune protein - and that leads to signalling of other immune cells to come and join the party,” said study leader Prof Hardev Pandha, from the University of Surrey and Royal Surrey County Hospital. The researchers from the University of Sussex who carried out the study said their findings could “help revolutionise treatment” for bladder cancer and reduce the risk of it recurring. Non-muscle invasive bladder cancer is the 10th most common cancer in the UK and affects around 10,000 new people every year. At present, treatments are either invasive, or cause toxic side effects. Moreover, constant, costly monitoring is required to ensure the cancer has not returned. Bladder cancer costs the NHS more per patient than any other cancer because of its high rate of recurrence.